Mavenclad® Cladribine – Have your Say by Friday 22nd September 2023
Mavenclad® Cladribine – Have your Say MSNZ is currently preparing a submission to Pharmac to urge them to again consider funding Mavenclad (Cladribine) for Relapsing Remitting MS. Our submission is due this Friday 22nd September. Real world and clinical trial data shows the treatment benefits for those with Relapsing Remitting MS. It is also available […]